1 in 8 Adults in the US Has Taken Ozempic or Another GLP-1 Drug—But What Does This Mean for Obesity Worldwide?

As research continues, it’s becoming clearer that GLP-1 receptor agonists have much more to offer than just blood sugar control.

The SELECT trial was a massive study involving over 17,600 people across 41 countries. This trial focused on individuals with obesity or overweight